Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about MAIA, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Beta-Thioguanine Deoxyriboside | Carcinoma, Non-Small -Cell Lung | Phase 3 · NCT06908304 | Recruiting |
| Gemcitabine Hydrochloride | Carcinoma, Non-Small -Cell Lung | Phase 3 · NCT06908304 | Recruiting |
| Cadonilimab | Resectable Hepatocellular Carcinoma | Early Phase 1 · NCT07446257 | Recruiting |
Also used in these trials (approved or third-party drugs, not MAIA's own candidates): Cemiplimab, Docetaxel Anhydrous, Vinorelbine.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
MAIA holds $21.3M in cash and short-term investments and burns about $6.3M/quarter from operations, an estimated runway of 10.1 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 38 · Moderate
On April 8, 2026, we announced that net proceeds from the $33 million confidentially marketed public offering of common stock in March 2026 are expected to fully fund the Company’s ongoing pivotal Phase 3 clinical trial of its lead investigational therapy, ateganosine, as a treatment for non-small cell lung cancer…10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MAIA files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Solas Capital Management, LLC | Institution (13F) | 3,030,845 | 4.91% | 2026-09-30 |
| Vanguard Capital Management LLC | Institution (13F) | 2,413,270 | 3.91% | 2026-09-30 |
| Vlad Vitoc Chief Executive Officer, Director, 10% o · +2.40M options |
Insider | 1,259,221 | 2.04% | 2026-09-14 |
| Ngar Yee Louie Director · +294,367 options |
Insider | 1,248,888 | 2.02% | 2025-12-22 |
| Centric Wealth Management | Institution (13F) | 1,167,070 | 1.89% | 2026-09-30 |
| 683 Capital Management LLC | Institution (13F) | 1,066,666 | 1.73% | 2026-09-30 |
| Ramiro Guerrero Director · +370,814 options |
Insider | 773,296 | 1.25% | 2026-09-10 |
| Geode Capital Management, LLC | Institution (13F) | 584,401 | 0.95% | 2026-09-30 |
| Bleichroeder LP | Institution (13F) | 500,000 | 0.81% | 2026-09-30 |
| Cristian Luput Director · +178,734 options |
Insider | 437,628 | 0.71% | 2025-11-26 |
| Renaissance Technologies, LLC | Institution (13F) | 399,100 | 0.65% | 2026-09-30 |
| Blackrock Inc. | Institution (13F) | 394,772 | 0.64% | 2026-09-30 |
Share count 61,750,308 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-09-30 filed 2026-10-02 |
CHAOUKI STEVEN M |
Option award (A) | 32,774 | – | – |
| 2026-09-30 filed 2026-10-02 |
Guerrero Ramiro |
Option award (A) | 32,012 | – | – |
| 2026-09-30 filed 2026-10-02 |
Louie Ngar Yee |
Option award (A) | 39,634 | – | – |
| 2026-09-30 filed 2026-10-02 |
Luput Cristian |
Option award (A) | 33,536 | – | – |
| 2026-09-30 filed 2026-10-02 |
Smith Stan |
Option award (A) | 38,871 | – | – |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MAIA and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →